Search Results

Search for "Rituximab" returned 8 results

Showing 1-8 out of 8

DrugBank ID	Name	Formula	Weight
DB00073	Rituximab	C₆₄₁₆H₉₈₇₄N₁₆₈₈O₁₉₈₇S₄₄	143859.7000
DB00073	Rituximab Rituxan binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.
DB00839	Tolazamide	C₁₄H₂₁N₃O₃S	311.4000
DB00839	Use caution at lower doses of Amifostine. Rituximab Additive hypotensive effects may occur. Consider withholding Tolazamide for 12 hours prior to administration of Rituximab. Somatropin ...
DB01021	Trichlormethiazide	C₈H₈Cl₃N₃O₄S₂	380.6560
DB01021	Rituximab Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Trichlormethiazide for 12 hours prior to administration of Rituximab. 6-chloro-3 ...
DB01162	Terazosin	C₁₉H₂₅N₅O₄	387.4329
DB01162	Initiate concomitant therapy cautiously. Rituximab Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration ...
DB00966	Telmisartan	C₃₃H₃₀N₄O₂	514.6169
DB00966	Telmisartan should be withheld prior to and throughout Rituximab administration. Spironolactone Telmisartan may increase the hyperkalemic effect of Spironolactone. Monitor for increased serum ...
DB00214	Torasemide	C₁₆H₂₀N₄O₃S	348.4200
DB00214	... withholding Torasemide for 12 hours prior to administration of Rituximab. Sulfadiazine Sulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 ...
DB00519	Trandolapril	C₂₄H₃₄N₂O₅	430.5372
DB00519	Rituximab Trandolapril may incresae the hypotensive effect of Rituximab. Salsalate The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy ...
DB00072	Trastuzumab	C₆₄₇₀H₁₀₀₁₂N₁₇₂₆O₂₀₁₃S₄₂	145531.5000
DB00072	Monitor closely for signs and symptoms of adverse events. Rituximab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. Sirolimus ...

Showing 1-8 out of 8

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.